MX2015012882A - Compuestos y composiciones terapeuticos. - Google Patents
Compuestos y composiciones terapeuticos.Info
- Publication number
- MX2015012882A MX2015012882A MX2015012882A MX2015012882A MX2015012882A MX 2015012882 A MX2015012882 A MX 2015012882A MX 2015012882 A MX2015012882 A MX 2015012882A MX 2015012882 A MX2015012882 A MX 2015012882A MX 2015012882 A MX2015012882 A MX 2015012882A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- therapeutic compounds
- compounds
- general formula
- pyruvate kinase
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000013009 Pyruvate Kinase Human genes 0.000 abstract 2
- 108020005115 Pyruvate Kinase Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/072688 WO2014139144A1 (en) | 2013-03-15 | 2013-03-15 | Therapeutic compounds and compositions |
| PCT/CN2014/000260 WO2014139325A1 (en) | 2013-03-15 | 2014-03-13 | Therapeutic compounds and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015012882A true MX2015012882A (es) | 2015-12-03 |
Family
ID=51535825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012882A MX2015012882A (es) | 2013-03-15 | 2014-03-13 | Compuestos y composiciones terapeuticos. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20160046579A1 (enExample) |
| EP (1) | EP2970189B1 (enExample) |
| JP (2) | JP6374413B2 (enExample) |
| CN (1) | CN105121425A (enExample) |
| AR (1) | AR095557A1 (enExample) |
| AU (1) | AU2014231564B2 (enExample) |
| BR (1) | BR112015023760A2 (enExample) |
| CA (1) | CA2903067A1 (enExample) |
| CL (1) | CL2015002767A1 (enExample) |
| CR (1) | CR20150571A (enExample) |
| ES (1) | ES2803548T3 (enExample) |
| HK (1) | HK1216175A1 (enExample) |
| IL (1) | IL241352A0 (enExample) |
| MX (1) | MX2015012882A (enExample) |
| NI (1) | NI201500140A (enExample) |
| PE (1) | PE20151793A1 (enExample) |
| PH (1) | PH12015502161A1 (enExample) |
| RU (1) | RU2015143908A (enExample) |
| SG (1) | SG11201507332SA (enExample) |
| TW (1) | TW201444797A (enExample) |
| WO (2) | WO2014139144A1 (enExample) |
| ZA (1) | ZA201506487B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139144A1 (en) * | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| CN104817490B (zh) * | 2015-05-13 | 2017-10-13 | 北京大学 | 氨基二硫代甲酸酯类化合物及其制备方法与应用 |
| WO2017100599A1 (en) | 2015-12-09 | 2017-06-15 | Luc Therapeutics | Thienopyrimidinone nmda receptor modulators and uses thereof |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
| AR111295A1 (es) * | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| CN107298685A (zh) * | 2017-06-29 | 2017-10-27 | 上海合全药业股份有限公司 | 一种8‑(叔丁氧羰基)‑1‑氧杂‑8‑氮杂螺[4.5]癸烷‑2‑羧酸的合成方法 |
| EP3668513B1 (en) | 2017-08-15 | 2021-11-10 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in treating blood disorders |
| KR20200125758A (ko) | 2017-10-27 | 2020-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 피리딘 카보닐 유도체 및 trpc6 억제제로서 이의 치료학적 용도 |
| ES2987073T3 (es) | 2018-08-02 | 2024-11-13 | Dev Ct Biotechnology | Proceso regioselectivo de un solo paso para sintetizar 2-hidroxiquinoxalina |
| PT3830092T (pt) | 2018-08-03 | 2023-07-25 | Novartis Ag | Moduladores do recetor nmda heteroaromáticos e suas utilizações |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| ES3010713T3 (en) * | 2018-12-18 | 2025-04-04 | D Western Therapeutics Inst Inc | Isoquinoline sulfonyl chloride acid addition salts and method of manufacture thereof |
| WO2021029450A1 (ko) * | 2019-08-09 | 2021-02-18 | 한국화학연구원 | 신규한 피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| CA3188340A1 (en) | 2020-08-13 | 2022-02-17 | Boehringer Ingelheim International Gmbh | Treatment of cognitive impairement associated with schizophrenia |
| KR20230088761A (ko) | 2020-10-13 | 2023-06-20 | 베링거 인겔하임 인터내셔날 게엠베하 | 재가공하는 방법 |
| CN112773800B (zh) * | 2021-01-25 | 2021-10-15 | 南通大学 | 哌啶-1-二硫代甲酸-3-甲基-1，4-二氧-1，4-二氢萘-2-甲基酯的用途 |
| WO2022170200A1 (en) | 2021-02-08 | 2022-08-11 | Global Blood Therapeutics, Inc. | 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CN117337292A (zh) | 2021-05-12 | 2024-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物 |
| BR112023020381A2 (pt) * | 2021-05-12 | 2023-11-21 | Boehringer Ingelheim Int | Derivados de piridina com substituintes cíclicos ligados por c como inibidores de cgas |
| TWI841134B (zh) | 2021-12-21 | 2024-05-01 | 大陸商賽諾哈勃藥業（成都）有限公司 | 含二氮雜亞基磺醯結構的化合物及其在醫藥上的用途 |
| CN115073422A (zh) * | 2022-07-28 | 2022-09-20 | 成都普瑞熙药业有限公司 | 一种制备4-(1-甲基-1h-吡唑-5-基)哌啶及其盐的方法 |
| ES2975743A1 (es) * | 2022-11-22 | 2024-07-12 | Moehs Iberica Sl | Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos |
| WO2024245143A1 (zh) | 2023-05-26 | 2024-12-05 | 赛诺哈勃药业（成都）有限公司 | 含二氮杂亚基磺酰结构化合物的药物组合物在治疗贫血相关疾病中的用途 |
| WO2025191185A1 (en) * | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Azine-based compounds as par-2 inhibitors and therapeutic uses thereof |
| WO2025233901A1 (en) | 2024-05-09 | 2025-11-13 | Biohaven Therapeutics Ltd. | Activators of pyruvate kinase isoform m2 and methods for treating neurodegenerative disease |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE508815A (enExample) | 1949-07-23 | |||
| GB935538A (en) | 1959-04-06 | 1963-08-28 | Stop Motion Devices Corp | Stop-motion head for use on knitting machines |
| US4474599A (en) | 1982-07-14 | 1984-10-02 | The Dow Chemical Company | 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents |
| GB8325370D0 (en) | 1983-09-22 | 1983-10-26 | Fujisawa Pharmaceutical Co | Benzoxazoline and benzothiazoline derivatives |
| JPS61129129A (ja) | 1984-11-28 | 1986-06-17 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| FI855180L (fi) | 1985-01-18 | 1986-07-19 | Nissan Chemical Ind Ltd | Pyrazolsulfonamidderivat, foerfarande foer dess framstaellande och det innehaollande ograesgift. |
| EP0246749A3 (en) | 1986-05-17 | 1988-08-31 | AgrEvo UK Limited | Triazole herbicides |
| JPS6339875A (ja) | 1986-08-05 | 1988-02-20 | Nissin Food Prod Co Ltd | ピリミジン誘導体 |
| US4775762A (en) | 1987-05-11 | 1988-10-04 | The Dow Chemical Company | Novel (1H-1,2,3-triazol-1-yl)pyridines |
| DE3813885A1 (de) | 1988-04-20 | 1989-11-02 | Schering Ag | 1-chlorpyrimidinyl-1h-1,2,4-triazol-3-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung |
| DE3813886A1 (de) | 1988-04-20 | 1989-11-02 | Schering Ag | 1-triazinyl-1h-1,2,4-triazol-3- sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung |
| US5220028A (en) | 1988-10-27 | 1993-06-15 | Nissan Chemical Industries, Ltd. | Halogeno-4-methylpyrazoles |
| MY106533A (en) | 1990-02-20 | 1995-06-30 | Sumitomo Chemical Co | A 4-tert.-butyl imidazole derivative and its production and use. |
| CA2036148A1 (en) | 1990-06-29 | 1991-12-30 | Hiroki Tomioka | A 1-phenylimidazole derivative and its production and use |
| ES2130166T3 (es) | 1990-12-31 | 1999-07-01 | Monsanto Co | Reduccion de la interaccion de pesticidas en cosechas. |
| US5252590A (en) | 1991-06-28 | 1993-10-12 | Sumitomo Chemical Company, Limited | 1-pyridylimidazole derivative |
| JPH0625177A (ja) | 1992-07-09 | 1994-02-01 | Nissan Chem Ind Ltd | ピラゾール誘導体及び除草剤 |
| JP3719612B2 (ja) | 1993-06-14 | 2005-11-24 | 塩野義製薬株式会社 | ヘテロ環を含有する尿素誘導体 |
| DE19541146A1 (de) | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
| FR2744449B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| BR9815453A (pt) | 1997-03-11 | 2001-10-23 | Du Pont | Composto, composição herbicida e método para controle do crescimento de vegetação indesejada |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| DE19743435A1 (de) | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| JP2002523451A (ja) | 1998-09-01 | 2002-07-30 | ブリストル−マイヤーズ スクイブ カンパニー | カリウムチャネル抑制剤および方法 |
| CZ2001959A3 (cs) | 1998-09-18 | 2001-12-12 | Basf Aktiengesellschaft | 4-Aminopyrrolopyrimidiny jako inhibitory kinasy |
| US6492408B1 (en) | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| CZ2002773A3 (cs) | 1999-09-04 | 2002-06-12 | Astrazeneca Ab | Substituované deriváty N-fenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamidu, které zvyąují aktivitu pyruvátdehydrogenázy |
| JP2002193710A (ja) | 2000-12-25 | 2002-07-10 | Kumiai Chem Ind Co Ltd | ピリミジン又はトリアジン誘導体及び農園芸用殺菌剤 |
| EP1387679A4 (en) | 2001-05-07 | 2004-08-11 | Smithkline Beecham Corp | SULPHONAMIDES |
| DE60226875D1 (de) | 2001-08-15 | 2008-07-10 | Du Pont | Orthosubstituierte arylamide zur bekämpfung von wirbellosen schädlingen |
| JP2003081937A (ja) | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
| WO2003037252A2 (en) | 2001-10-30 | 2003-05-08 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1472248A1 (en) | 2002-01-17 | 2004-11-03 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| ES2306859T3 (es) | 2002-03-13 | 2008-11-16 | Janssen Pharmaceutica Nv | Derivados de sulfonil como nuevos inhibidores de histona deacetilasa. |
| AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| GB0215775D0 (en) | 2002-07-06 | 2002-08-14 | Astex Technology Ltd | Pharmaceutical compounds |
| CA2494962C (en) | 2002-08-09 | 2011-06-14 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| KR20050059294A (ko) | 2002-10-24 | 2005-06-17 | 스테릭스 리미티드 | 11-베타-하이드록시 스테로이드 데하이드로게나제 형태 1및 형태 2의 억제제 |
| CN1744899A (zh) * | 2002-12-13 | 2006-03-08 | 史密丝克莱恩比彻姆公司 | 作为ccr5拮抗剂的哌啶衍生物 |
| DE602004027171D1 (de) * | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
| EP1635800A2 (en) | 2003-06-10 | 2006-03-22 | Kalypsys, Inc. | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease |
| US6818631B1 (en) | 2003-08-15 | 2004-11-16 | Nippon Soda Co. Ltd. | Fungicidal pyrimidine derivatives |
| US20080051414A1 (en) | 2003-10-14 | 2008-02-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| JP2008514590A (ja) | 2004-09-24 | 2008-05-08 | アストラゼネカ・アクチエボラーグ | ベンゾイミダゾール誘導体、それを含む組成物、その製造方法及びその使用 |
| WO2006038594A1 (ja) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| WO2006043950A1 (en) | 2004-10-20 | 2006-04-27 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| EP1807417A2 (en) | 2004-11-04 | 2007-07-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
| SE0402762D0 (sv) | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Indazole sulphonamide derivatives |
| WO2006117762A2 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Antimicrobial agents |
| EP1910321A4 (en) | 2005-07-05 | 2010-09-01 | Astrazeneca Ab | NEW COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6-MEDIATED ILLNESSES SUCH AS ALZHEIMER'S DISEASE, COGNITIVE ILLUSTRATIONS, SCHOISOPHRENIC ASSOCIATED COGNITIVE DISORDERS, OBESITAS AND PARKINSON DISEASE |
| US20080214495A1 (en) | 2005-07-08 | 2008-09-04 | Astrazeneca Ab | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa |
| TW200730485A (en) | 2005-07-29 | 2007-08-16 | Kalypsys Inc | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| US7345178B2 (en) | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| JP2007238458A (ja) | 2006-03-06 | 2007-09-20 | D Western Therapeutics Institute Inc | 新規なイソキノリン誘導体及びこれを含有する医薬 |
| CN101448803A (zh) | 2006-03-17 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 用作5-ht6调节剂的四氢萘 |
| AU2007231594A1 (en) | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| AU2007281911B2 (en) | 2006-08-04 | 2014-02-06 | Beth Israel Deaconess Medical Center | Inhibitors of pyruvate kinase and methods of treating disease |
| US20090247499A1 (en) | 2006-08-21 | 2009-10-01 | Fletcher Joan M | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
| US7994094B2 (en) | 2006-09-01 | 2011-08-09 | Otsuka Agritechno Co., Ltd. | N-pyridylpiperidine compound, method for producing the same, and pest control agent |
| EP2527345B1 (en) | 2006-10-16 | 2015-12-16 | Thesan Pharmaceuticals, Inc. | Therapeutic pyrazolyl thienopyridines |
| HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| CL2008000835A1 (es) * | 2007-03-23 | 2008-10-03 | Icagen Inc Pfizer Ltd | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm |
| PA8790401A1 (es) | 2007-07-18 | 2009-03-31 | Janssen Pharmaceutica Nv | Sulfonamidas como moduladores de trpm8 |
| US20110224252A1 (en) | 2007-10-26 | 2011-09-15 | Syngenta Crop Protection, Inc. | Novel imidazole derivatives |
| EP2053045A1 (en) | 2007-10-26 | 2009-04-29 | Syngenta Participations AG | Novel imidazole derivatives |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| BRPI0917575A2 (pt) * | 2008-08-05 | 2019-09-24 | Targegen Inc | métodos de tratamento de talassemia |
| JP2012500783A (ja) * | 2008-08-22 | 2012-01-12 | エヴォテック・アクチエンゲゼルシャフト | 新しいブラジキニンｂ１拮抗薬 |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| ES2620634T3 (es) | 2008-10-09 | 2017-06-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Activadores de piruvato quinasa humana |
| JP5756457B2 (ja) | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ， インコーポレイテッド | ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法 |
| AU2010239188B2 (en) | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| PL2427441T3 (pl) | 2009-05-04 | 2017-06-30 | Agios Pharmaceuticals, Inc. | Aktywatory PKM2 do stosowania w leczeniu raka |
| WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| PE20120693A1 (es) * | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
| US20130035304A1 (en) | 2010-01-29 | 2013-02-07 | Walensky Loren D | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| BR112012021806A2 (pt) | 2010-03-01 | 2015-09-08 | Myrexis Inc | compostos e seus usos terapêusticos. |
| US20130109672A1 (en) | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
| FR2967674B1 (fr) | 2010-11-23 | 2012-12-14 | Pf Medicament | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
| US9221792B2 (en) * | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
| EP2704720B1 (en) * | 2011-05-03 | 2019-08-07 | Agios Pharmaceuticals, Inc. | Pyruvate kinase r activators for use in therapy |
| CN102805860A (zh) * | 2011-05-30 | 2012-12-05 | 复旦大学 | 丙酮酸激酶2乙酰化抑制剂及其用途 |
| WO2014139144A1 (en) * | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
-
2013
- 2013-03-15 WO PCT/CN2013/072688 patent/WO2014139144A1/en not_active Ceased
-
2014
- 2014-03-13 AU AU2014231564A patent/AU2014231564B2/en not_active Ceased
- 2014-03-13 EP EP14765650.8A patent/EP2970189B1/en active Active
- 2014-03-13 CA CA2903067A patent/CA2903067A1/en not_active Abandoned
- 2014-03-13 US US14/776,635 patent/US20160046579A1/en not_active Abandoned
- 2014-03-13 WO PCT/CN2014/000260 patent/WO2014139325A1/en not_active Ceased
- 2014-03-13 ES ES14765650T patent/ES2803548T3/es active Active
- 2014-03-13 JP JP2015561914A patent/JP6374413B2/ja not_active Expired - Fee Related
- 2014-03-13 RU RU2015143908A patent/RU2015143908A/ru not_active Application Discontinuation
- 2014-03-13 CN CN201480021459.8A patent/CN105121425A/zh active Pending
- 2014-03-13 MX MX2015012882A patent/MX2015012882A/es unknown
- 2014-03-13 BR BR112015023760A patent/BR112015023760A2/pt not_active IP Right Cessation
- 2014-03-13 SG SG11201507332SA patent/SG11201507332SA/en unknown
- 2014-03-13 HK HK16104168.0A patent/HK1216175A1/zh unknown
- 2014-03-13 PE PE2015002010A patent/PE20151793A1/es not_active Application Discontinuation
- 2014-03-14 TW TW103109338A patent/TW201444797A/zh unknown
- 2014-03-14 US US14/210,583 patent/US9108921B2/en active Active
- 2014-03-17 AR ARP140101179A patent/AR095557A1/es unknown
-
2015
- 2015-07-31 US US14/814,862 patent/US9365545B2/en active Active
- 2015-09-03 ZA ZA2015/06487A patent/ZA201506487B/en unknown
- 2015-09-09 IL IL241352A patent/IL241352A0/en unknown
- 2015-09-15 PH PH12015502161A patent/PH12015502161A1/en unknown
- 2015-09-15 CL CL2015002767A patent/CL2015002767A1/es unknown
- 2015-09-16 NI NI201500140A patent/NI201500140A/es unknown
- 2015-10-15 CR CR20150571A patent/CR20150571A/es unknown
-
2017
- 2017-03-07 JP JP2017042775A patent/JP2017105832A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014231564B2 (en) | 2018-07-12 |
| IL241352A0 (en) | 2015-11-30 |
| US20140288081A1 (en) | 2014-09-25 |
| EP2970189A4 (en) | 2016-08-10 |
| US9365545B2 (en) | 2016-06-14 |
| CR20150571A (es) | 2016-01-06 |
| AU2014231564A2 (en) | 2015-10-22 |
| SG11201507332SA (en) | 2015-10-29 |
| AR095557A1 (es) | 2015-10-28 |
| NI201500140A (es) | 2015-11-24 |
| WO2014139144A1 (en) | 2014-09-18 |
| RU2015143908A (ru) | 2017-04-21 |
| JP6374413B2 (ja) | 2018-08-15 |
| PE20151793A1 (es) | 2015-12-10 |
| US20150336931A1 (en) | 2015-11-26 |
| WO2014139325A1 (en) | 2014-09-18 |
| AU2014231564A1 (en) | 2015-09-10 |
| EP2970189B1 (en) | 2020-05-06 |
| US9108921B2 (en) | 2015-08-18 |
| ZA201506487B (en) | 2016-11-30 |
| US20160046579A1 (en) | 2016-02-18 |
| TW201444797A (zh) | 2014-12-01 |
| CN105121425A (zh) | 2015-12-02 |
| BR112015023760A2 (pt) | 2017-07-18 |
| CA2903067A1 (en) | 2014-09-18 |
| ES2803548T3 (es) | 2021-01-27 |
| PH12015502161A1 (en) | 2016-01-25 |
| JP2017105832A (ja) | 2017-06-15 |
| JP2016512203A (ja) | 2016-04-25 |
| EP2970189A1 (en) | 2016-01-20 |
| CL2015002767A1 (es) | 2016-12-30 |
| HK1216175A1 (zh) | 2016-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502161A1 (en) | Therapeutic compounds and compositions | |
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
| MX342274B (es) | Actividades de la piruvato quinasa m2 (pkm2). | |
| IN2015DN01156A (enExample) | ||
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| MX2015010921A (es) | Compuestos de carbazol utiles como inhibidores de bromodominio. | |
| PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
| NZ720478A (en) | Autotaxin inhibitor compounds | |
| ZA201603342B (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| PH12016500582A1 (en) | Heterocyclic compounds and uses thereof | |
| MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX2016008150A (es) | Formulaciones de berberina y usos de las mismas. | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| MX371343B (es) | Moduladores del receptor x hepatico (lxr). | |
| MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
| EA201590615A1 (ru) | Стимулирующие лактацию композиции на основе фосфатидилсерина | |
| MX2015016760A (es) | Derivados de ftalazina. | |
| NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| EA201491695A1 (ru) | Лечение рака ингибиторами tor-киназы |